The effects of thalidomide on the stimulation of NF-κB activity and TNF-α production by lipopolysaccharide in a human colonic epithelial cell line

Molecules and Cells

Volumn 17, Issue 2, 2004, Pages 210-216

  Kim, You Sun ^a   Kim, Joo Sung ^b   Jung, Hyun Chae ^b   Song, In Sung ^b  

^a Inje University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Inflammatory bowel disease; Nuclear factor B; Thalidomide; Tumor necrosis factor

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1;

ARTICLE; CELL LINE; CELL STIMULATION; CELL STRAIN HT29; COLON MUCOSA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; COLON; DRUG EFFECT; ENTERITIS; GENE EXPRESSION REGULATION; GENETICS; HISTOLOGY; IMMUNOLOGY; METABOLISM;

CELL LINE; COLON; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; NF-KAPPA B; RNA, MESSENGER; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3442884264     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ardite, E., Panes, J., Miranda, M., Salas, A., Elizalde, J. I., Sans, M., Arce, Y., Bordas, J. M., Fernandez-Checa, J. C., and Pique, J. M. (1998) Effects of steroid treatment on activation of nuclear factor kappa B in patients with inflammatory bowel disease. Br. J. Pharmacol. 124, 431-433.
2. Auphan, N., Di Donato, J. A., Rosette, C., Helmberg, A., and Karin, M. (1995) Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270, 286-290.
3. Barnes, P. J. and Karin, M. (1997) Nuclear factor κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066-1071.
4. Bauditz, J., Wedel, S., and Lochs, H. (2002) Thalidomide reduces tumor necrosis factor and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50, 196-200.
5. Conroy, C. A. and Cattell, R. (2001) Infliximab treatment for Crohn's disease. Postgrad. Med. J. 77, 436-440.
6. Corral, L. G. and Kaplan, G. (1999) Immunomodulation by thalidomide and thalidomide analogues. Ann. Rheum. Dis. 58, 1107-1113.
7. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082-4085.
8. Eckmmann, L., Kagnoff, M. F., and Fierer, J. (1993) Epithelial cell secrete the chemokine interleukin-8 in response to bacterial entry. Infect. Immun. 61, 4569-4574.
9. Ehrenpreis, E. D., Kane, S. V., Cohen, L. B., Cohen, R. D., and Hanauer, S. B. (1999) Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117, 1271-1277.
10. Gibson, U. E., Heid, C. A., and Williams, P. M. (1996) A novel method for real time quantitative RT-PCR. Genome Res. 6, 995-1001.
11. Kaiser, G. C., Yan, F., and Polk, D. B. (1999) Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor κ B activation in mouse colonocytes. Gastroenterology 116, 602-609.
12. Kane, S., Stone, L. J., and Ehrenpreis, E. (2002) Thalidomide as salvage therapy for patients with delayed hypersensitivity response to infliximab. J. Clin. Gastroenterol. 35, 149-150.
13. Keifer, J. A., Guttridge, D. C., Ashburner, B. P., and Baldwin, A. S. (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem. 276, 22382-22387.
14. Lokensgard, J. R., Hu, S., Fenema, E. M., Sheng, W. S., and Peterson, P. K. (2000) Effect of thalidomide on chemokine production by human microglia. J. Infect. Dis. 182, 983-987.
15. Lopez-Talavera, J. C., Cadelina, G., Olchowski, J., Merrill, W., and Groszmann, R. J. (1996) Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 23, 1616-1621.
16. 2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J. Immunol. 168, 2644-2651.
17. Marriott, J. B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G., Shire, M. G., Stirling, D., and Dalgleish, A. G. (1998) CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J. Immunol. 161, 4236-4243.
18. May, M. J. and Ghosh, S. (1998) Signal transduction through NF-κB. Immunol. Today 19, 80-88.
19. Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J., Young, D. B., Barbosa, M., Mann, M., Manning, A., and Rao, A. (1997) IKK-1 and IKK-2: cytokine-activated IkB kinases essential for NF-κB activation. Science 278, 860-866.
20. Moller, D. R., Wysocka, M., Greenlee, B. M., Ma, X., Wahl, L., Flockhart, D. A., Trinchieri, G., and Karp, C. L. (1997) Inhibition of IL-12 production by thalidomide. J. Immunol. 159, 5157-5161.
21. Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., and Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177, 1675-1680.
22. Moreira, A. L., Corral, L. G., Ye, W., Johnson, B., Stirling, D., Muller, G. W., Freedman, V. H., and Kaplan, G. (1997) Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res. Hum. Retroviruses 13, 857-863.
23. Mukaida, N., Morita, M., Ishikawa, Y., Rice, N., Okamoto, S., Kasahara, T., and Matsushima, K. (1994) Novel mechanism of glucocorticoid-mediated gene repression: NF-κB is a target for glucocorticoid-mediated IL-8 gene repression. J. Biol. Chem. 269, 289-295.
24. Neurath, M. F., Pettersson, S., Meyer, Z., Buschenfelde, K. H., and Strober, W. (1996) Local administration of antisense phosphrothioate oligonucleotides to the p65 subunit of NF-kappaB abrogates established experimenral colitis in mice. Nat. Med. 2, 998-1004.
25. Nikolaus, S., Bauditz, J., Gionchetti, P., Witt, C., Lochs, H., and Schreiber, S. (1998) Increased secretion of proinflammatory cytokines by circulation polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 42, 470-476.
26. Oliver, S. J., Cheng, T. P., Banquerigo, M. L., and Brahn, E. (1998) The effect of thalidomide and 2 analogs on collagen induced arthritis. J. Rheumatol. 25, 964-969.
27. Pallone, F. and Monteleone, G. (1996) Regulatory cytokines in inflammatory bowel disease. Aliment. Pharmacol. Ther. 10, 75-79.
28. Peterson, P. K., Hu, S., Sheng, W. S., Kravitz, F. H., Molitor, T. W., Chatterjee, D., and Chao, C. C. (1995) Thalidomide inhibits tumor necrosis factor-α production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J. Infet. Dis. 172, 1137-1140.
29. Plevy, S. E., Landers, C. J., Prehn, J., Carramanzana, N. M., Deem, R. L., Shealy, D., and Targan, S. R. (1997) A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. 159, 6276-6282.
30. Rogler, G., Brand, K., Vogl, D., Page, S., Hofmeister, R., Andus, T., Knuechel, R., Baeuerle, P. A., Scholmerich, J., and Gross, V. (1998) Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115, 357-369.
31. Rowland, T., McHugh, S. M., Deighton, J., Ewan, P. W., Dearman, R. J., and Kimber, I. (2001) Differential effect of thalidomide and dexamethasone on the transcription factor NF-κB. Int. Immunopharm. 1, 49-61.
32. Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., and Kaplan, G. (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699-703.
33. Sampaio, E. P., Kaplan, G., Miranda, A., Nery, J. A., Miguel, C. P., Viana, S. M., and Sarno, E. N. (1993) The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168, 408-414.
34. Schmid, R. M., Liptay, S., Betts, J. C., and Nabel, G. J. (1994) Structural and functional analysis of NF-kappa B. Determinants of DNA binding specificity and protein interaction. J. Biol. Chem. 269, 32162-32167.
35. Schottelius, A. J. and Balbwin, A. S. (1999) A role for transcription factor NF-κB in intestinal inflammation. Int. J. Colorectal. Dis. 14, 18-28.
36. Schreiber, S., Nikolaus, S., and Hampe, J. (1998) Activation of nuclear factor kappa B in inflammatory bowel disease. Gut 42, 477-485.
37. Shek, L. P. and Lim, D. L. (2002) Thalidomide in Behcet's disease. Biomed. Pharmacother. 56, 31-35.
38. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J., and Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571.
39. Stack, W. A., Mann, S. D., Roy, A. J., Heath, P., Sopwith, M., Freeman, J., Holmes, G., Long, R., Forbes, A., and Kamm, M. A. (1997) Randomised controlled trial of CDP571 anti-body to tumor necrosis factor-alpha in Crohn's disease. Lancet 349, 521-524.
40. Targan, S. R., Hanauer, S. B., van Deventer, S. J., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., and Rutgeerts, P. J. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N. Engl. J. Med. 337, 1029-1035.
41. 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor α production. Proc. Natl. Acad. Sci. USA 93, 7552-7556.
42. van Dullemen, H, M., van Deventer, S. J., Hommes, D. W., Bijl, H. A., Jansen, J., Tytgat, G. N., and Woody, J. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129-135.
43. Vasiliauskas, E. A., Kam, L. Y., Abreu-Martin, M. T., Hassard, P. V., Papadakis, K. A., Yang, H., Zeldis, J. B., and Targan, S. R. (1999) An open-label pilot study of low-dose thalidomide in chronically active, steroid dependent Crohn's disease. Gastroenterology 117, 1278-1287.
44. Wahl, C., Liptay, S., Adler, G., and Schmid, R. M. (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 101, 1163-1174.
45. Weber, C. K., Liptay, S., Wirth, T., Adler, G., and Schmid, R. M. (2000) Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology 119, 1209-1218.